The clinical and economic burden related to nonalcoholic fatty liver disease (NAFLD) is turning into of paramount significance for country-wide health systems globally. Most latest records suggest that about 25% of adults may be classified as NAFLD one in four to five sufferers with NAFLD have non-alcoholic steatohepatitis (NASH), and 1.5% have advanced fibrosis, the hallmark of disease progression to cirrhosis. Type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD) typically exist together. It has appeared as a manifestation of metabolic syndrome.

The incidence of Nonalcoholic fatty liver disease(NAFLD) in T2DM is as high as 60%, and T2DM will increase the risk of disease progression to cirrhosis in addition to the prevalence of hepatocellular carcinoma (HCC). The relationship between T2DM and NAFLD seems to be bidirectional, with T2DM increasing the risk of NAFLD and NAFLD favoring the development of altered glucose regulation and T2DM. Initially considered the hepatic manifestation of metabolic syndrome, and consequently, as a possible impact of diabetes. It has also been cautioned that liver fats accumulation and NAFLD may certainly be the metabolic driver of T2DM. This proof makes the development of T2DM further outcome of NAFLD treatment and prompts the need for strict control of glucose metabolism in NAFLD cases.

The presentations of NAFLD variety from simple steatosis (NAFL), nonalcoholic steatohepatitis (NASH) to cirrhosis. NAFLD has an incidence of 70% amongst T2DM sufferers. Overweight/obesity and insulin resistance (IR) had been strongly connected with NAFLD. Noninvasive evaluation and staging of disease are primarily based totally on clinical parameters which include age, sex, liver function test, platelet count, lipid profile, BMI, and imaging modalities which include USG, transient elastography (TE), and magnetic resonance imaging mass spectroscopy. Such clinical scoring systems and TE are beneficial withinside the early detection of NAFLD and predicting fibrosis. The principle behind the control of NAFLD with T2DM includes an indirect impact via improvement in IR and glycemia and for this reason, is used for the treatment of T2DM as well.